Inclusion Criteria:  Aged ≥22 years with newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016). Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. No prior therapy for ALL such as chemotherapy and radiation therapy before signing the informed consent except for limited treatment (≤7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine.  Exclusion Criteria:  Patients with Philadelphia chromosome positive ALL, Burkitt's leukemia, mixed lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia per WHO classification (2016). Patients with Down syndrome. Patients with Hepatitis B (positive for HBs antigen), and Hepatitis C (HCV antibody) at inclusion Participants known to be HIV-positive. Known history of non-gallstone-related pancreatitis. Known severe hepatic impairment (bilirubin >3 x upper limit of normal [ULN]; transaminases >10 times ULN.